Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer is a research paper published in Cancer Cell (2025). On theSindex it has a DataRank of 0.477. It has been cited 23 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.477
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: K12 CA088084
NCI NIH HHS
Grant: P30 CA016672
National Institutes of Health National Cancer Institute
Grant: 1R01CA271682-01A1
National Institutes of Health National Cancer Institute
Grant: P50CA221707-01A1
NCI NIH HHS
Grant: R01 CA218230
NCI NIH HHS
Grant: R50 CA285403
NCI NIH HHS
Grant: U01 CA200468
NCI NIH HHS
Grant: R01 CA271682
NCI NIH HHS
Grant: P50 CA221707
National Institutes of Health
Andrew Sabin Family Foundation
Bristol-Myers Squibb
Break Through Cancer
The University of Texas MD Anderson Cancer Center
Khalifa Bin Zayed Al Nahyan Foundation
Pfizer
MeSH Terms
Keywords